期刊文献+

GTF2H2通过介导AKT信号通路影响肝癌细胞Hep3B的增殖和迁移

GTF2H2 Affects the Proliferation and Migration of Hep3B Hepatocellular Carcinoma Cells by Mediating AKT Signal Pathway
原文传递
导出
摘要 目的:探讨通用转录因子II H亚基2(GTF2H2)是否影响肝癌细胞Hep3B的增殖和迁移及其潜在的分子机制。方法:通过转染GTF2H2-siRNA构建GTF2H2敲低的Hep3B肝癌细胞模型;实时定量聚合酶链反应(q-RT-PCR)和蛋白质印迹实验检测肝癌细胞Hep3B的GTF2H2敲低效果;细胞计数实验(MTS)检测GTF2H2敲低的肝癌细胞Hep3B的增殖能力;Transwell细胞迁移实验检测GTF2H2敲低的肝癌细胞Hep3B的迁移能力;蛋白质印迹分析实验检测GTF2H2敲低后是否影响肿瘤相关分子信号通路。结果:GTF2H2敲低组的Hep3B细胞的增殖能力较对照组的Hep3B细胞增强,迁移能力亦有增强;蛋白质印迹实验显示GTF2H2敲低后,p-AKT通路蛋白的表达明显升高。结论:GTF2H2可能通过介导AKT分子信号通路,影响肝癌细胞Hep3B的增殖和迁移能力。 Objective:To investigate whether General transcription factorⅡsubunit 2(GTF2H2)affects the proliferation and migration of Hep3B cells and the underlying molecular mechanism.Methods:The GTF2H2 knockdown Hep3B cell model was constructed by transfecting GTF2H2-siRNA.Quantitative real-time polymerase chain reaction and Western blotting were used to detect the GTF2H2 knockdown effect in Hep3B cells.MTS cell proliferation assay kit was used to detect the proliferation ability of GTF2H2 knockdown Hep3B cells.The migration ability of GTF2H2 knockdown Hep3B cells was evaluated by cell Transwell assay.Western blotting was used to detect whether GTF2H2 knockdown affects tumor associated molecular signaling pathway.Results:The proliferation and migration ability of GTF2H2 knockdown Hep3B cells was stronger than that of the controls.Western blotting showed that the expression of p-AKT pathway protein in GTF2H2 knockdown Hep3B cells was significantly increased.Conclusion:GTF2H2 may affect the proliferation and migration ability of Hep3B cells by the regulation of the AKT molecular signal pathway.
作者 欧阳琴 李艳萌 徐安健 周冬虎 李振坤 黄坚 OUYANG Qin;LI Yan-meng;XU An-jian;ZHOU Dong-hu;LI Zhen-kun;HUANG Jian(Experimental Center,Beijing Friendship Hospital,Beijing Institute of Clinical Medicine,Beijing 100875,China)
出处 《中国生物工程杂志》 CAS CSCD 北大核心 2021年第6期4-12,共9页 China Biotechnology
基金 国家自然科学基金(81650014)资助项目。
关键词 HEP3B GTF2H2 P-AKT 增殖 迁移 Hep3B GTF2H2 p-AKT Proliferation Migration
  • 相关文献

参考文献4

二级参考文献76

  • 1Yu-Jun Li,Yun-Xiao Meng,Xiang-Rui Ji the Department of Pathology. Affiliated Hospital of Medical College, Qingdao University, Qingdao 266003, China.Relationship between expressions of E-cadherin and alpha-catenin and biological behaviors of human pancreatic cancer[J].Hepatobiliary & Pancreatic Diseases International,2003,2(2):471-477. 被引量:12
  • 2Theise ND. Liver cancer. In: WILD BWSCP, editor. World CancerReport 2014. World Health Organization, 2014: 576-592.
  • 3European Association For The Study Of The Liver; EuropeanOrganisation For Research And Treatment Of Cancer. EASLEORTCclinical practice guidelines: management of hepatocellularcarcinoma. J Hepatol 2012; 56: 908-943 [PMID: 22424438 DOI:10.1016/j.jhep.2011.12.001].
  • 4Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterialchemoembolization: modalities, indication, and patient selection.J Hepatol 2015; 62: 1187-1195 [PMID: 25681552 DOI: 10.1016/j.jhep.2015.02.010].
  • 5Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, TremosiniS, Ayuso C, Llovet JM, Real MI, Bruix J. Survival of patients withhepatocellular carcinoma treated by transarterial chemoembolisation(TACE) using Drug Eluting Beads. Implications for clinical practiceand trial design. J Hepatol 2012; 56: 1330-1335 [PMID: 22314428DOI: 10.1016/j.jhep.2012.01.008].
  • 6Takayasu K, Arii S, Kudo M, Ichida T, Matsui O, Izumi N,Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N,Makuuchi M. Superselective transarterial chemoembolizationfor hepatocellular carcinoma. Validation of treatment algorithmproposed by Japanese guidelines. J Hepatol 2012; 56: 886-892[PMID: 22173160 DOI: 10.1016/j.jhep.2011.10.021].
  • 7Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF,de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, PortaC, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, BorbathI, H鋟ssinger D, Giannaris T, Shan M, Moscovici M, Voliotis D,Bruix J. Sorafenib in advanced hepatocellular carcinoma. N EnglJ Med 2008; 359: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857].
  • 8Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, KudoM, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens FA, QianJ, McKee MD, Ricker JL, Carlson DM, El-Nowiem S. Linifanibversus Sorafenib in patients with advanced hepatocellular carcinoma:results of a randomized phase III trial. J Clin Oncol 2015; 33:172-179 [PMID: 25488963 DOI: 10.1200/jco.2013.54.3298].
  • 9Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, ChungHC, Song X, Xu J, Poggi G, Omata M, Pitman Lowenthal S,Lanzalone S, Yang L, Lechuga MJ, Raymond E. Sunitinib versussorafenib in advanced hepatocellular cancer: results of a randomizedphase III trial. J Clin Oncol 2013; 31: 4067-4075 [PMID: 24081937DOI: 10.1200/jco.2012.45.8372].
  • 10Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, VanLaethem JL, Van Vlierberghe H, Trojan J, Kolligs FT, Weiss A, MilesS, Gasbarrini A, Lencioni M, Cicalese L, Sherman M, Gridelli C,Buggisch P, Gerken G, Schmid RM, Boni C, Personeni N, HassounZ, Abbadessa G, Schwartz B, Von Roemeling R, Lamar ME,Chen Y, Porta C. Tivantinib for second-line treatment of advancedhepatocellular carcinoma: a randomised, placebo-controlled phase2 study. Lancet Oncol 2013; 14: 55-63 [PMID: 23182627 DOI:10.1016/s1470-2045(12)70490-4].

共引文献132

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部